Overview

A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease

Status:
Terminated
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
No Dimebon clinical data exist yet in patients with disease that has advanced to the moderate-to-severe stage. Therefore, this study evaluates the safety and efficacy of Dimebon in patients with moderate-to-severe AD who are receiving existing background therapy with memantine.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Collaborator:
Medivation, Inc.